MYC and neoplasm: However, given the largely “undruggable” properties of MYC, clinically applicable MYC-directed therapies remain elusive and the focus has shifted to targeting proteins regulating the stability of MYC oncoproteins, disrupting protein–protein interactions with MYC cofactors or exploiting dependencies of MYC-addicted tumor cells [17].